In prostate cancer, CTC enumeration remains the most extensively validated prognostic marker to date [114], but other clinically relevant phenotypes like androgen receptor (AR) localization or the presence of the AR-V7 splice variant are also in clinical practice. Here, AR is linked to prostate carcinoma.